Alnylam Pharmaceuticals, Inc. (ALNY) — Financial statements
Income statement, balance sheet, and cash flow for Alnylam Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3,714↑65.2% | 2,248↑23.0% | 1,828↑76.2% | 1,037↑22.9% | 844 | |
| Cost of Revenue | 677↑109.4% | 323↑4.2% | 310↑83.9% | 169↑20.5% | 140 | |
| Gross Profit | 3,037↑57.8% | 1,925↑26.8% | 1,518↑74.8% | 869↑23.4% | 704 | |
| Operating Expenses | ||||||
| R&D Expenses | 1,324↑17.6% | 1,126↑12.1% | 1,004↑13.7% | 883↑11.5% | 792 | |
| General & Administrative Expenses | 0.00↓100.0% | 976↑22.6% | 796↑3.2% | 771↑24.2% | 621 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 1,211↑24.1% | 976↑22.6% | 796↑3.2% | 771↑24.2% | 621 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -2 | |
| Operating Expenses | 2,535↑20.6% | 2,102↑16.8% | 1,800↑8.9% | 1,654↑17.0% | 1,413 | |
| Total Costs & Expenses | 3,212↑32.5% | 2,425↑14.9% | 2,110↑15.8% | 1,822↑17.4% | 1,553 | |
| Operating Results | ||||||
| Operating Income | 502↑383.6% | -177↑37.3% | -282↑64.1% | -785↓10.8% | -709 | |
| Depreciation & Amortization | 56↓1.8% | 57↑4.8% | 54↑21.6% | 44↓6.5% | 48 | |
| EBITDA | 557↑411.6% | -179↑30.7% | -258↑72.1% | -927↓40.1% | -662 | |
| EBIT | 502↑313.0% | -236↑24.6% | -312↑67.8% | -971↓36.9% | -709 | |
| Interest & Other Income | ||||||
| Net Interest Income | -141↓610.5% | -20↑22.6% | -26↑80.4% | -131↑7.3% | -141 | |
| Interest Income | 111↓8.6% | 122↑27.7% | 96↑285.2% | 25↑1471.1% | 2 | |
| Interest Expense | 253↑78.1% | 142↑17.0% | 121↓22.3% | 156↑9.1% | 143 | |
| Non-Operating Income | 0.00↓100.0% | 59↑94.7% | 30↓83.8% | 186↑39380.5% | 0.47 | |
| Other Income / Expenses | -178↑11.0% | -200↓32.5% | -151↑55.7% | -342↓138.3% | -143 | |
| Income Before Tax | 323↑185.6% | -377↑13.0% | -434↑61.5% | -1,127↓32.3% | -852 | |
| Income Tax Expense | 9↑109.5% | -99↓1575.4% | 7↑61.5% | 4↑512.2% | 0.68 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 314↑212.8% | -278↑36.8% | -440↑61.1% | -1,131↓32.6% | -853 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 314↑212.8% | -278↑36.8% | -440↑61.1% | -1,131↓32.6% | -853 | |
| Bottom-Line Net Income | 314↑212.8% | -278↑36.8% | -440↑61.1% | -1,131↓32.6% | -853 | |
| EPS (Basic) | 2.39↑209.6% | -2.18↑38.1% | -3.52↑62.2% | -9.30↓29.2% | -7.20 | |
| EPS (Diluted) | 2.33↑206.9% | -2.18↑38.1% | -3.52↑62.2% | -9.30↓29.2% | -7.20 | |
| Weighted Average Shares | 131↑2.6% | 128↑2.2% | 125↑2.6% | 122↑2.7% | 118 | |
| Weighted Average Diluted Shares | 135↑5.5% | 128↑2.2% | 125↑2.6% | 122↑2.7% | 118 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.